|
PHF23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.27190000035016E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.41679999998701E-06 |
| Normal-vs-Stage2 |
8.22089999999998E-05 |
| Normal-vs-Stage3 |
1.97824000000013E-05 |
| Normal-vs-Stage4 |
4.165800E-04 |
| Stage1-vs-Stage2 |
2.542600E-01 |
| Stage1-vs-Stage3 |
8.449000E-01 |
| Stage1-vs-Stage4 |
7.861600E-01 |
| Stage2-vs-Stage3 |
2.310400E-01 |
| Stage2-vs-Stage4 |
4.501400E-01 |
| Stage3-vs-Stage4 |
6.924800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.23219999981217E-07 |
| Normal-vs-AfricanAmerican |
3.592000E-04 |
| Normal-vs-Asian |
1.773860E-04 |
| Caucasian-vs-AfricanAmerican |
5.671200E-01 |
| Caucasian-vs-Asian |
9.163200E-01 |
| AfricanAmerican-vs-Asian |
5.343000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.82740000000048E-05 |
| Normal-vs-Female |
2.45389999986578E-07 |
| Male-vs-Female |
8.409600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.81999999995897E-06 |
| Normal-vs-Age(41-60Yrs) |
5.99990000016426E-07 |
| Normal-vs-Age(61-80Yrs) |
1.951630E-04 |
| Normal-vs-Age(81-100Yrs) |
2.323800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.142600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.663200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.030800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.028400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.196000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.378400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.744000E-01 |
| Classical-VS-Follicular |
5.016500E-03 |
| Classical-VS-Other |
1.026610E-01 |
| Classical-VS-Normal |
4.19939971685324E-10 |
| Tall-VS-Follicular |
1.982770E-01 |
| Tall-VS-Other |
2.243600E-01 |
| Tall-VS-Normal |
4.844000E-04 |
| Follicular-VS-Other |
8.153200E-01 |
| Follicular-VS-Normal |
3.537700E-02 |
| Other-VS-Normal |
3.876800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.0835999999913E-05 |
| Normal-vs-N1 |
1.030410E-02 |
| N0-vs-N1 |
3.953400E-01 |
|
|
